Autres langues CSPC Pharmaceutical Group Limited

Actions

1093

HK1093012172

Produits pharmaceutiques

Temps Différé Hong Kong S.E. 08:07:31 16/09/2026			Varia. 5j.	Varia. 1 janv.
8,800 ^HKD	+1,15 %		-3,30 %	+4,39 %

15/09	CSPC Pharmaceutical obtient le statut de 'thérapie innovante' pour un traitement contre le cancer du poumon	MT
15/09	CSPC Pharmaceutical : le SYS6010 obtient le statut de thérapie innovante auprès de la NMPA	RE

Autres langues

15/09	CSPC Pharmaceutical Gets Breakthrough Therapy Designation for Lung Cancer Drug
15/09	CSPC Pharmaceutical says SYS6010 granted breakthrough therapy designation by NMPA
09/09	CSPC Pharma's SYH9087 Injection Gets China Nod for Parkinson's Disease Trial
09/09	CSPC Pharma Gets Clinical Trial Nod in China for Solid Tumors Drug
09/09	CSPC Pharmaceutical Group Limited Announces Dopamine Receptor Agonist Rotigotine Long-Acting Injection (SYH9087 Injection)
09/09	CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval In China For Goserelin Sustained-Release Injection (SYH9102 Injection)
08/09	CSPC Pharmaceutical Group Limited SYH2083 Eye Drops Obtain Clinical Trial Approval In China
08/09	CSPC Pharmaceutical Gets China Approval for Eye Drug Clinical Trials
07/09	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial of SYH2085 Tablets for Treatment of Uncomplicated Influenza in Adults in China
07/09	CSPC Pharma Begins Phase II Study of Influenza Drug in China
01/09	CSPC Pharma's Cancer Drug Gets Breakthrough Therapy Designation for New Indication in China
01/09	CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China
01/09	CSPC Pharma Initiates Depression Drug Candidate Trial in China
01/09	CSPC Pharmaceutical Group Limited Initiates Phase I Clinical Trial Of SYH2056 Tablets For The Treatment Of Depression In China
01/09	CSPC Pharmaceutical Group Limited Receives Breakthrough Therapy Designation For SYS6010 For Treatment Of Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
31/08	CSPC Pharma Begins Trial for Weight Management Drug in China
31/08	Cspc Pharmaceutical Group Limited Initiates Phase I Clinical Trial of Syh2092 Injection for Weight Management in Adult Patients with Overweight or Obesity At the First Centre in China
28/08	Cspc Pharmaceutical Group Limited Initiates Phase Ii Clinical Trial of Syh2069 Injection for Weight Management in Adult Patients with Overweight or Obesity At the First Centre in China
27/08	CSPC Pharma Gets Trial Nod for Weight Management Drug in China
27/08	CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval In China For SYH2092 Injection
26/08	CSPC Pharma's Colorectal Cancer Drug Candidate Gets Fast Track Designation by US FDA
26/08	CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint
26/08	CSPC Pharmaceutical Group Limited Reports Sys6090 Grants Fast Track Designation by U.S. Fda for Treatment of Patients with Mss/Pmmr Mcrc
26/08	CSPC Pharmaceutical Group Limited Reports SYS6010 Meets Primary Endpoint In Phase III Clinical Study For EGFR-Mutated NSCLC
25/08	CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For Recombinant Respiratory Syncytial Virus Vaccine SYS6057 In The U.S